Introduction/Aim. Polypharmacy can increase the risk of side effects and cause adverse drug interactions with a significant impact on the course of the basic disease. The aim of the study was to determine the frequency of polypharmacy and examine its impact on the risk of drug-drug interactions in patients with rheumatoid arthritis (RA). The research was conducted in the form of a retrospective cross-sectional study. Material and methods. The study included 131 patients diagnosed with RA, treated during 2019 and 2020. Demographic data and clinical characteristics of the subjects were collected from the medical documentation (presence of comorbidities, prescribed therapy and number of drugs). In the study, polypharmacy was defined as the use of more than five drugs, regardless of the length of therapy. Results. The data analysis of the therapy used by patients showed that 84 subjects (64.12%) used 5 - 9 drugs, both for the treatment of primary and for the treatment of other present acute and chronic diseases. The analysis of the collected results identified potential interactions in 86 respondents (65.65%), while the total number of potential interactions was 164. The most common potential interactions were serious (73.78%). Analyzing the obtained results, it appears that aceclofenac is the drug that has the potential to enter into the largest number of interactions with the drugs used in the therapy of RA. Conclusion. Given the wide range of available drugs and therapeutic modalities used in the treatment of RA, it is necessary to choose the right combination of drugs in order to achieve the desired therapeutic outcomes and minimize potential drug-drug interactions.
References
1.
McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiology and Drug Safety. 2007;16(1):65–73.
2.
Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, et al. Potenciais interações medicamentosas em pacientes com artrite reumatoide. Revista Brasileira de Reumatologia. 51(1):29–39.
3.
Gomides APM, Albuquerque CP, Santos ABV, Amorim RBC, Bértolo MB, Júnior PL, et al. High Levels of Polypharmacy in Rheumatoid Arthritis—A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study. Journal of Pharmacy Practice. 2021;34(3):365–71.
4.
Ma SN, Zaman Huri H, Yahya F. <p>Drug-related problems in patients with rheumatoid arthritis</p> Therapeutics and Clinical Risk Management. Volume 15:505–24.
5.
Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International. 2020;40(4):511–21.
6.
COLEBATCH AN, MARKS JL, van der HEIJDE DM, EDWARDS CJ. Safety of Nonsteroidal Antiinflammatory Drugs and/or Paracetamol in People Receiving Methotrexate for Inflammatory Arthritis: A Cochrane Systematic Review. The Journal of Rheumatology Supplement. 2012;90(0):62–73.
7.
Arava SA. UK Summary of product characteristics. 2009;
8.
E.M.E.A. EMEA public statement on leflunomide (Arava)-severe and serious hepatic reactions. 2001;
9.
Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate. Annals of Pharmacotherapy. 2003;37(1):149–149.
10.
Krstić N, Stefanović N, Gocić V, Ilić K, Damnjanović I. INFLUENCE OF POLYPHARMACY ON THE FUNCTIONAL ABILITY OF PATIENTS WITH RHEUMATOID ARTHRITIS. Acta Medica Medianae. 2022;61(4):24–30.
11.
Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases. 2009;68(7):1105–12.
12.
Simponi. Centocor Ortho Biotech Inc. 2009.
13.
Davies B, Shaw T. Rituximab pharmacokinetic characteristics are not influenced by combination with methotrexate or cyclophosphamide. Annals of the Rheumatic Diseases. 2004;63:0128.
14.
June CRAPH. 2015;
15.
KATCHAMART W, BOURRÉ-TESSIER J, DONKA T, DROUIN J, ROHEKAR G, BYKERK VP, et al. Canadian Recommendations for Use of Methotrexate in Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 2010;37(7):1422–30.
16.
New Safety Information: Interaction of Proton Pump Inhibitors (PPIs.
17.
Bornstein C, Craig M, Tin D. Practice guidelines for pharmacists. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2014;147(2):97–109.
18.
Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing Cost by Reducing Polypharmacy: The Polypharmacy Outcomes Project. Journal of the American Medical Directors Association. 2012;13(9):818.e11-818.e15.
19.
Pivec N, Serdinšek T, Klemenc-Ketiš Z, Kersnik J. Prevalence of Disease Symptoms in Slovenian Adult Population and Factors Associated with their Prevalence. Slovenian Journal of Public Health. 2014;53(3):262–9.
20.
Stojanović S, Stamenković B, Nedović J, Aleksić I, Cvetković J. Effectiveness of Tocilizumab after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis: A single-centre experience. Acta Facultatis Medicae Naissensis. 2021;38(3):247–56.
21.
Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road. Arthritis Care & Research. 2008;59(6):757–9.
22.
Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, et al. Potenciais interações medicamentosas em pacientes com artrite reumatoide. Revista Brasileira de Reumatologia. 51(1):29–39.
23.
National Center for Health Statistics. Healthy People 2000 Final Review. 2001;
24.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1).
25.
Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International. 2020;40(4):511–21.
26.
Zelko E, KlemencKetis Z, TusekBunc K. Medication Adherence in Elderly with Polypharmacy Living at Home: a Systematic Review of Existing Studies. Materia Socio Medica. 2016;28(2):129.
27.
Softič N, Smogavec M, Klemenc-Ketiš Z, Kersnik J. Prevalence of chronic diseases among adult Slovene population. Slovenian Journal of Public Health. 2011;50(3).
28.
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. The Lancet. 2010;376(9746):1094–108.
29.
Menditto E, Gimeno Miguel A, Moreno Juste A, Poblador Plou B, Aza Pascual-Salcedo M, Orlando V, et al. Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis. PLOS ONE. 14(2):e0210701.
30.
Nobili A, Garattini S, Mannucci PM. Multiple Diseases and Polypharmacy in the Elderly: Challenges for the Internist of the Third Millennium. Journal of Comorbidity. 2011;1(1):28–44.
31.
Zhang N, Sundquist J, Sundquist K, Ji J. An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study. Frontiers in Pharmacology. 11.
32.
Milton JC, Hill-Smith I, Jackson SHD. Prescribing for older people. BMJ. 2008;336(7644):606–9.
33.
Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiology and Drug Safety. 2010;19(9):977–82.
34.
Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. Diabetes Research and Clinical Practice. 2010;87(3):385–93.
35.
Hermann M, Carstens N, Kvinge L, Fjell A, Wennersberg M, Folleso K, et al. Polypharmacy and Potential Drug–Drug Interactions in Home-Dwelling Older People – A Cross-Sectional Study. Journal of Multidisciplinary Healthcare. Volume 14:589–97.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
